|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001563,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0039593,
umls-concept:C0070166,
umls-concept:C0220825,
umls-concept:C0348016,
umls-concept:C0522523,
umls-concept:C0597357,
umls-concept:C1152760,
umls-concept:C1522318,
umls-concept:C1707689,
umls-concept:C1999216,
umls-concept:C2699007,
umls-concept:C2934030
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-7-5
|
|
pubmed:abstractText |
Despite current dual-antiplatelet therapy with aspirin and clopidogrel, adverse clinical events continue to occur during and after percutaneous coronary intervention (PCI). The failure of clopidogrel to provide optimal protection may be related to delayed onset of action, interpatient variability in its effect, and an insufficient level of platelet inhibition. Furthermore, the irreversible binding of clopidogrel to the P2Y(12) receptor for the life span of the platelet is associated with increased bleeding risk especially during urgent or emergency surgery. Novel antiplatelet agents are required to improve management of patients undergoing PCI. Elinogrel is a potent, direct-acting (ie, non-prodrug), selective, competitive, and reversible P2Y(12) inhibitor available in both intravenous and oral formulations. The INNOVATE-PCI study is a phase 2 randomized, double-blind, clopidogrel-controlled trial to evaluate the safety, tolerability, and preliminary efficacy of this novel antiplatelet agent in patients undergoing nonurgent PCI.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/P2RY12 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Purinergic P2 Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolinones,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P2Y12,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Ticlopidine,
http://linkedlifedata.com/resource/pubmed/chemical/Troponin,
http://linkedlifedata.com/resource/pubmed/chemical/clopidogrel,
http://linkedlifedata.com/resource/pubmed/chemical/elinogrel
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
pubmed-author:BhattDeepak LDL,
pubmed-author:GibsonC MichaelCM,
pubmed-author:GretlerDaniel DDD,
pubmed-author:HarringtonRobert ARA,
pubmed-author:HuberKurtK,
pubmed-author:KochmanJanuszJ,
pubmed-author:LeonardiSergioS,
pubmed-author:MadanMinaM,
pubmed-author:McClureMatthew WMW,
pubmed-author:PaynterGayle EGE,
pubmed-author:RaoSunil VSV,
pubmed-author:RoeMatthew TMT,
pubmed-author:ThompsonVivianV,
pubmed-author:WelshRobert CRC,
pubmed-author:ZeymerUweU
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 Mosby, Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
160
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
65-72
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20598974-Administration, Oral,
pubmed-meshheading:20598974-Adolescent,
pubmed-meshheading:20598974-Adult,
pubmed-meshheading:20598974-Aged,
pubmed-meshheading:20598974-Angioplasty, Balloon, Coronary,
pubmed-meshheading:20598974-Coronary Artery Disease,
pubmed-meshheading:20598974-Double-Blind Method,
pubmed-meshheading:20598974-Drug Tolerance,
pubmed-meshheading:20598974-Female,
pubmed-meshheading:20598974-Follow-Up Studies,
pubmed-meshheading:20598974-Humans,
pubmed-meshheading:20598974-Injections, Intravenous,
pubmed-meshheading:20598974-Male,
pubmed-meshheading:20598974-Middle Aged,
pubmed-meshheading:20598974-Platelet Aggregation Inhibitors,
pubmed-meshheading:20598974-Purinergic P2 Receptor Antagonists,
pubmed-meshheading:20598974-Quinazolinones,
pubmed-meshheading:20598974-Receptors, Purinergic P2Y12,
pubmed-meshheading:20598974-Sulfonamides,
pubmed-meshheading:20598974-Ticlopidine,
pubmed-meshheading:20598974-Time Factors,
pubmed-meshheading:20598974-Treatment Outcome,
pubmed-meshheading:20598974-Troponin,
pubmed-meshheading:20598974-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
|
|
pubmed:affiliation |
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA. sergio.leonardi@duke.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
